1. Home
  2. GCBC vs CTNM Comparison

GCBC vs CTNM Comparison

Compare GCBC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greene County Bancorp Inc.

GCBC

Greene County Bancorp Inc.

N/A

Current Price

$35.47

Market Cap

606.1M

Sector

Finance

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$10.08

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GCBC
CTNM
Founded
1889
2009
Country
United States
United States
Employees
227
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
606.1M
550.7M
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
GCBC
CTNM
Price
$35.47
$10.08
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $21.43
AVG Volume (30 Days)
18.8K
★ 659.1K
Earning Date
10-22-2026
11-03-2026
Dividend Yield
★ 1.24%
N/A
EPS Growth
★ 31.69
0.46
EPS
★ 0.73
N/A
Revenue
★ $4,117,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$48.75
★ N/A
Revenue Growth
★ 11.06
N/A
52 Week Low
$21.38
$6.73
52 Week High
$37.25
$17.79

Technical Indicators

Market Signals
Indicator
GCBC
CTNM
Relative Strength Index (RSI) 46.76 50.10
Support Level $33.55 $8.59
Resistance Level $35.84 $13.72
Average True Range (ATR) 0.92 0.81
MACD -0.12 0.30
Stochastic Oscillator 10.48 71.40

Price Performance

Historical Comparison
GCBC
CTNM

About GCBC Greene County Bancorp Inc.

Greene Bancorp Inc is the holding company. Through its subsidiaries, the company operates as a provider of community-based banking services throughout the Hudson Valley and Capital Region of New York State. Its customers include individuals, businesses, municipalities and other institutions.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: